John Libbey Eurotext

Annales de Biologie Clinique


Blood lipid tests in 2017 Volume 75, issue 6, Novembre-Décembre 2017


  • Figure 1


1 Service de biochimie, Hôpital Armand Trousseau, AP-HP, Paris, France
2 Service de biochimie métabolique, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, AP-HP, Paris, France
3 Service de biochimie, Hôpital européen Georges Pompidou, AP-HP, Paris, France
4 Service de biochimie, Hôpital de Bicêtre, AP-HP, Le Kremlin-Bicêtre, France
* Tirés à part
  • Key words: lipid tests, cholesterol, triacylglycerols, cardio-vascular risk, recommendation
  • DOI : 10.1684/abc.2017.1303
  • Page(s) : 646-52
  • Published in: 2017

Strong epidemiological evidence supports a causal relationship between dyslipidemia and atherosclerotic cardio-vascular disease, which remains the leading cause of death and morbidity worldwide. A lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides) is recommended at the initial evaluation for the assessment of the cardio-vascular risk. A commentary of the lipid profile for the clinician and mostly for the patient should be stated on the lab report. Quantifying the cardio-vascular risk using the SCORE (systematic coronary risk estimation) system, as recommended by the Haute autorité de santé (HAS), is the starting point to establish therapeutic goals and treatment strategies. It may be important to emphasize therapeutic goals in lipid reports in order to better monitor lipid profiles at appropriate intervals to assess compliance and therapeutic efficacy for patients on lipid lowering therapy.